Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery

Milena Nasi, Marcello Pinti, Elisabetta Chiesa, Simona Fiore, Serena Manzini, Cinzia Del Giovane, Roberto D'Amico, Nicoletta Palai, Carlo Campatelli, Francesca Sabbatini, Marianna Roccio, Cecilia Tibaldi, Giulia Masuelli, Cristina Mussini, Enrico Ferrazzi, Antonella D'Arminio Monforte, Andrea Cossarizza

Research output: Contribution to journalArticle

Abstract

Background: Increasing numbers of pregnant HIV-positive women are receiving combination antiretroviral regimens for preventing mother-to-child virus transmission or for treating the infection itself. Several studies have demonstrated that nucleoside reverse transcriptase inhibitors (NRTIs) induce mitochondrial toxicity by several mechanisms, including depletion of mitochondrial DNA (mtDNA). By the quantification of mtDNA levels, we studied mitochondrial toxicity in HIV-positive women at delivery and the possible correlations with antiretroviral regimens, viroimmunological and metabolic parameters. Methods: We analysed 68 HIV-positive women enrolled in the Italian Prospective Cohort Study on Efficacy and Toxicity of Antiretroviral in Pregnancy (TARGET Study); all were taking ≥1 NRTI. We quantified mtDNA copies per cell in subcutaneous fat samples collected during delivery. At the 3rd, 6th and 9th month of pregnancy, we collected data concerning CD4+ T-cell count, plasma HIV RNA, total and high-density lipoprotein (HDL) cholesterol, fasting plasma glucose and triglycerides. As a control, we analysed mtDNA levels in abdominal subcutaneous fat samples from 23 HIV-seronegative women at delivery. Results: mtDNA content was significantly lower in HIV-infected women when compared with HIV-negative controls. mtDNA content varied independently from viroimmunological, lipid and glucose parameters at the different months, with the exceptions of triglycerides at the 9th month and of HDL at the 6th month of pregnancy. Conclusions: In subcutaneous tissue from women taking NRTI-based antiretroviral regimens, we observed a significant decrease of mtDNA content, compared with uninfected women not on antiviral treatment. Moreover, a significant correlation was noted between mtDNA content and HDL cholesterol and triglycerides.

Original languageEnglish
Pages (from-to)365-372
Number of pages8
JournalAntiviral Therapy
Volume16
Issue number3
DOIs
Publication statusPublished - 2011

Fingerprint

Subcutaneous Fat
Mitochondrial DNA
HIV
Reverse Transcriptase Inhibitors
Nucleosides
Therapeutics
Pregnancy
HDL Cholesterol
Triglycerides
Abdominal Subcutaneous Fat
Glucose
Subcutaneous Tissue
HDL Lipoproteins
CD4 Lymphocyte Count
Antiviral Agents
Fasting
Cohort Studies
Mothers
Prospective Studies
RNA

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Nasi, M., Pinti, M., Chiesa, E., Fiore, S., Manzini, S., Del Giovane, C., ... Cossarizza, A. (2011). Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery. Antiviral Therapy, 16(3), 365-372. https://doi.org/10.3851/IMP1764

Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery. / Nasi, Milena; Pinti, Marcello; Chiesa, Elisabetta; Fiore, Simona; Manzini, Serena; Del Giovane, Cinzia; D'Amico, Roberto; Palai, Nicoletta; Campatelli, Carlo; Sabbatini, Francesca; Roccio, Marianna; Tibaldi, Cecilia; Masuelli, Giulia; Mussini, Cristina; Ferrazzi, Enrico; D'Arminio Monforte, Antonella; Cossarizza, Andrea.

In: Antiviral Therapy, Vol. 16, No. 3, 2011, p. 365-372.

Research output: Contribution to journalArticle

Nasi, M, Pinti, M, Chiesa, E, Fiore, S, Manzini, S, Del Giovane, C, D'Amico, R, Palai, N, Campatelli, C, Sabbatini, F, Roccio, M, Tibaldi, C, Masuelli, G, Mussini, C, Ferrazzi, E, D'Arminio Monforte, A & Cossarizza, A 2011, 'Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery', Antiviral Therapy, vol. 16, no. 3, pp. 365-372. https://doi.org/10.3851/IMP1764
Nasi, Milena ; Pinti, Marcello ; Chiesa, Elisabetta ; Fiore, Simona ; Manzini, Serena ; Del Giovane, Cinzia ; D'Amico, Roberto ; Palai, Nicoletta ; Campatelli, Carlo ; Sabbatini, Francesca ; Roccio, Marianna ; Tibaldi, Cecilia ; Masuelli, Giulia ; Mussini, Cristina ; Ferrazzi, Enrico ; D'Arminio Monforte, Antonella ; Cossarizza, Andrea. / Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery. In: Antiviral Therapy. 2011 ; Vol. 16, No. 3. pp. 365-372.
@article{6a53ccb7641046329542ad72dc6f2afa,
title = "Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery",
abstract = "Background: Increasing numbers of pregnant HIV-positive women are receiving combination antiretroviral regimens for preventing mother-to-child virus transmission or for treating the infection itself. Several studies have demonstrated that nucleoside reverse transcriptase inhibitors (NRTIs) induce mitochondrial toxicity by several mechanisms, including depletion of mitochondrial DNA (mtDNA). By the quantification of mtDNA levels, we studied mitochondrial toxicity in HIV-positive women at delivery and the possible correlations with antiretroviral regimens, viroimmunological and metabolic parameters. Methods: We analysed 68 HIV-positive women enrolled in the Italian Prospective Cohort Study on Efficacy and Toxicity of Antiretroviral in Pregnancy (TARGET Study); all were taking ≥1 NRTI. We quantified mtDNA copies per cell in subcutaneous fat samples collected during delivery. At the 3rd, 6th and 9th month of pregnancy, we collected data concerning CD4+ T-cell count, plasma HIV RNA, total and high-density lipoprotein (HDL) cholesterol, fasting plasma glucose and triglycerides. As a control, we analysed mtDNA levels in abdominal subcutaneous fat samples from 23 HIV-seronegative women at delivery. Results: mtDNA content was significantly lower in HIV-infected women when compared with HIV-negative controls. mtDNA content varied independently from viroimmunological, lipid and glucose parameters at the different months, with the exceptions of triglycerides at the 9th month and of HDL at the 6th month of pregnancy. Conclusions: In subcutaneous tissue from women taking NRTI-based antiretroviral regimens, we observed a significant decrease of mtDNA content, compared with uninfected women not on antiviral treatment. Moreover, a significant correlation was noted between mtDNA content and HDL cholesterol and triglycerides.",
author = "Milena Nasi and Marcello Pinti and Elisabetta Chiesa and Simona Fiore and Serena Manzini and {Del Giovane}, Cinzia and Roberto D'Amico and Nicoletta Palai and Carlo Campatelli and Francesca Sabbatini and Marianna Roccio and Cecilia Tibaldi and Giulia Masuelli and Cristina Mussini and Enrico Ferrazzi and {D'Arminio Monforte}, Antonella and Andrea Cossarizza",
year = "2011",
doi = "10.3851/IMP1764",
language = "English",
volume = "16",
pages = "365--372",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "3",

}

TY - JOUR

T1 - Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery

AU - Nasi, Milena

AU - Pinti, Marcello

AU - Chiesa, Elisabetta

AU - Fiore, Simona

AU - Manzini, Serena

AU - Del Giovane, Cinzia

AU - D'Amico, Roberto

AU - Palai, Nicoletta

AU - Campatelli, Carlo

AU - Sabbatini, Francesca

AU - Roccio, Marianna

AU - Tibaldi, Cecilia

AU - Masuelli, Giulia

AU - Mussini, Cristina

AU - Ferrazzi, Enrico

AU - D'Arminio Monforte, Antonella

AU - Cossarizza, Andrea

PY - 2011

Y1 - 2011

N2 - Background: Increasing numbers of pregnant HIV-positive women are receiving combination antiretroviral regimens for preventing mother-to-child virus transmission or for treating the infection itself. Several studies have demonstrated that nucleoside reverse transcriptase inhibitors (NRTIs) induce mitochondrial toxicity by several mechanisms, including depletion of mitochondrial DNA (mtDNA). By the quantification of mtDNA levels, we studied mitochondrial toxicity in HIV-positive women at delivery and the possible correlations with antiretroviral regimens, viroimmunological and metabolic parameters. Methods: We analysed 68 HIV-positive women enrolled in the Italian Prospective Cohort Study on Efficacy and Toxicity of Antiretroviral in Pregnancy (TARGET Study); all were taking ≥1 NRTI. We quantified mtDNA copies per cell in subcutaneous fat samples collected during delivery. At the 3rd, 6th and 9th month of pregnancy, we collected data concerning CD4+ T-cell count, plasma HIV RNA, total and high-density lipoprotein (HDL) cholesterol, fasting plasma glucose and triglycerides. As a control, we analysed mtDNA levels in abdominal subcutaneous fat samples from 23 HIV-seronegative women at delivery. Results: mtDNA content was significantly lower in HIV-infected women when compared with HIV-negative controls. mtDNA content varied independently from viroimmunological, lipid and glucose parameters at the different months, with the exceptions of triglycerides at the 9th month and of HDL at the 6th month of pregnancy. Conclusions: In subcutaneous tissue from women taking NRTI-based antiretroviral regimens, we observed a significant decrease of mtDNA content, compared with uninfected women not on antiviral treatment. Moreover, a significant correlation was noted between mtDNA content and HDL cholesterol and triglycerides.

AB - Background: Increasing numbers of pregnant HIV-positive women are receiving combination antiretroviral regimens for preventing mother-to-child virus transmission or for treating the infection itself. Several studies have demonstrated that nucleoside reverse transcriptase inhibitors (NRTIs) induce mitochondrial toxicity by several mechanisms, including depletion of mitochondrial DNA (mtDNA). By the quantification of mtDNA levels, we studied mitochondrial toxicity in HIV-positive women at delivery and the possible correlations with antiretroviral regimens, viroimmunological and metabolic parameters. Methods: We analysed 68 HIV-positive women enrolled in the Italian Prospective Cohort Study on Efficacy and Toxicity of Antiretroviral in Pregnancy (TARGET Study); all were taking ≥1 NRTI. We quantified mtDNA copies per cell in subcutaneous fat samples collected during delivery. At the 3rd, 6th and 9th month of pregnancy, we collected data concerning CD4+ T-cell count, plasma HIV RNA, total and high-density lipoprotein (HDL) cholesterol, fasting plasma glucose and triglycerides. As a control, we analysed mtDNA levels in abdominal subcutaneous fat samples from 23 HIV-seronegative women at delivery. Results: mtDNA content was significantly lower in HIV-infected women when compared with HIV-negative controls. mtDNA content varied independently from viroimmunological, lipid and glucose parameters at the different months, with the exceptions of triglycerides at the 9th month and of HDL at the 6th month of pregnancy. Conclusions: In subcutaneous tissue from women taking NRTI-based antiretroviral regimens, we observed a significant decrease of mtDNA content, compared with uninfected women not on antiviral treatment. Moreover, a significant correlation was noted between mtDNA content and HDL cholesterol and triglycerides.

UR - http://www.scopus.com/inward/record.url?scp=79959485743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959485743&partnerID=8YFLogxK

U2 - 10.3851/IMP1764

DO - 10.3851/IMP1764

M3 - Article

C2 - 21555819

AN - SCOPUS:79959485743

VL - 16

SP - 365

EP - 372

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 3

ER -